Kelley-Ross & Associates, Inc.
Elyse Tung
The goal of this demonstration project or observational study is to evaluate the feasibility and acceptability of a pharmacist-managed cabotegravir long acting injectable for PrEP program in a community pharmacy setting. The main question it aims to answer are: Is the program feasible and acceptable at the end of 1 year of operations? What are the facilitators and barriers of the program? Participants who want to start the FDA approved cabotegravir long acting injectable medication for PrEP will have the option participating in surveys and a review of their electronic health records. Medication will be administered based on FDA approved labeling guidelines and their PrEP care will be part of standard of care per CDC. Pharmacists who want to provide the service to their patients will have the option of participating in surveys pre and post implementation.
HIV Infections
Cabotegravir Injection [Apretude]
| Study Type : | Observational |
| Estimated Enrollment : | 50 participants |
| Official Title : | Implementation and Delivery of Cabotegravir Long Acting Injection for PrEP in a Community Pharmacy Setting. |
| Actual Study Start Date : | June 1, 2023 |
| Estimated Primary Completion Date : | November 30, 2025 |
| Estimated Study Completion Date : | November 30, 2025 |
Information not available for Arms and Intervention/treatment
| Ages Eligible for Study: | 18 Years |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | Accepts Healthy Volunteers |
Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.
Not yet recruiting
Kelley-Ross Pharmacy at the Polyclinic
Seattle, Washington, United States, 98104
Not yet recruiting
Kelley-Ross Capitol Hill Pharmacy
Seattle, Washington, United States, 98122